UNITY is currently conducting a Phase 2b ASPIRE study to evaluate multiple doses of UBX1325 in a head-to-head comparison to aflibercept ... is an investigational compound being studied in retinal ...

The company said this morning that the COAST trial of sozinibercept (OPT-302) as a combination therapy with blockbuster wet AMD therapy Regeneron/Bayer's Eylea (aflibercept) wasn't able to show ...

The San Diego-based biotech's pipeline is headed by compounds that either block or ... from ophthalmic disease blockbuster Eylea (aflibercept) and "tangible growth" for prostate cancer drug ...

An FDA target action date of August 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License ...

High-dose aflibercept offers extended dosing intervals for DME and wet AMD, with sustained visual and anatomical improvements. The PULSAR and PHOTON trials showed efficacy in maintaining vision ...

According to the letter, the FDA did not agree with the proposition to include additional extended dosing intervals greater than 16 weeks. The Food and Drug Administration (FDA) has issued a ...

Back to Healio In this expert perspective, Manjot K. Gill, MD, discusses the potential FDA approval in 2025 of aflibercept 8 mg for the treatment of retinal vein occlusion. Gill, vice chair of ...

The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application (sBLA) for Eylea HD (aflibercept) injection 8mg for priority review.

for EYLEA HD ® (aflibercept) Injection 8 mg across all approved indications. The CRL did not identify any issues with the safety or efficacy of EYLEA HD in its approved indications and dosing ...

(NEXSTAR) – More than 170,000 bottles of Martinelli’s apple juice have been recalled over potential contamination with patulin, according to the U.S. Food and Drug Administration. Patulin, a ...